EP
OCUL icon

Essential Partners’s Ocular Therapeutix OCUL Stock Holding History

Essential Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.59K Buy
977
+682
+231% +$6.18K ﹤0.01% 1232
2026
Q1 		$2.5K Buy
295
+253
+602% +$2.41K ﹤0.01% 1911
2025
Q4 		$510 Sell
42
-9
-18% -$109 ﹤0.01% 2227
2025
Q3 		$596 Buy
51
+18
+55% +$215 ﹤0.01% 2164
2025
Q2 		$306 Buy
+33
New +$258 ﹤0.01% 1839

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Essential Partners's OCUL Position: Q2 2026 in Review

Essential Partners increased its Ocular Therapeutix (OCUL) stake by 231% in Q2 2026, buying an estimated $6.18K and bringing the position to 977 shares worth $9.59K. The position accounts for ﹤0.01% of the portfolio, ranked #1232.

Essential Partners first reported a position in OCUL in Q2 2025 and has held it in 5 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Essential Partners held 977 shares of Ocular Therapeutix worth $9.59K as of Q2 2026.
  • Essential Partners bought 682 Ocular Therapeutix shares in Q2 2026, an estimated $6.18K.
  • Ocular Therapeutix made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1232 holding.
  • Essential Partners first reported a position in Ocular Therapeutix in Q2 2025 and has held it in 5 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.